Development of an evaluation model to determine disease severity in COVID-19 using basic laboratory markers
Int J Lab Hematol
.
2022 Oct;44(5):e245-e249.
doi: 10.1111/ijlh.13912.
Epub 2022 Jun 16.
Authors
Ryosuke Maki
1
,
Yuki Horiuchi
2
,
Fumiaki Hayashi
3
,
Shuko Nojiri
4
,
Ikki Takehara
5
,
Yosuke Iwasaki
3
,
Kazunori Miyake
1
,
Takashi Miida
2
,
Tomohiko Ai
2
,
Yoko Tabe
2
6
Affiliations
1
Clinical Laboratory Medicine, Juntendo University Urayasu Hospital, Chiba, Japan.
2
Department of Clinical Laboratory Medicine, Juntendo University Graduate School of Medicine, Tokyo, Japan.
3
Scientific Affairs, Sysmex Corporation, Kobe, Japan.
4
Medical Technology Innovation Center, Juntendo University, Tokyo, Japan.
5
Reagent Engineering, Sysmex Corporation, Kobe, Japan.
6
Department of Next Generation Haematology Laboratory Medicine, Juntendo University Graduate School of Medicine, Tokyo, Japan.
PMID:
35712755
PMCID:
PMC9349754
DOI:
10.1111/ijlh.13912
No abstract available
Publication types
Letter
MeSH terms
Biomarkers
COVID-19*
Humans
SARS-CoV-2
Severity of Illness Index
Substances
Biomarkers